Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly, Merck Deals Mark Start Of New Era For Indian Drug Firms – PharmAsia News Spotlight

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - A new patent law to protect intellectual property and in-depth experience in clinical trials and manufacturing has helped Indian drug firms such as Piramal Healthcare become equal partners with multinational counterparts in sharing risks, costs and profits, according to a senior company executive

You may also be interested in...



China Emerging As Big Winner In Pharma Outsourcing Rush To Asia -- PwC

Asia's expanding wealth and markets for drugs, combined with a pool of scientific talent and strengthening protections for patents, propel pharmaceutical multinationals to step up operations in the region.

China Emerging As Big Winner In Pharma Outsourcing Rush To Asia - PwC

BEIJING - Asia's expanding wealth and markets for drugs, combined with a pool of scientific talent and strengthening protections for patents, are propelling pharmaceutical multinationals to step up operations in the region in drug manufacturing, research and clinical trials

China Emerging As Big Winner In Pharma Outsourcing Rush To Asia - PwC

BEIJING - Asia's expanding wealth and markets for drugs, combined with a pool of scientific talent and strengthening protections for patents, are propelling pharmaceutical multinationals to step up operations in the region in drug manufacturing, research and clinical trials

Related Content

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel